Oscar Health, Inc. Stock Prediction and Forecast [OSCR]
1 extracted signal · 1 resolved · 0 still active
StockInvest.usIndependent analyst profile- Source published
- 26 Nov 2025, 04:44 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
![Video preview for Oscar Health, Inc. Stock Prediction and Forecast [OSCR]](https://i.ytimg.com/vi/deyNjAuPgVA/hqdefault.jpg)
AI-generated source summary
Oscar Health (OSCR) presents a mixed technical outlook. While short-term indicators like MACD and Bollinger Bands suggest a buy signal, the stock is within a broad declining trend. The longer-term average and price action indicate bearish sentiment. The stock's price, currently at $16.73, is facing resistance at $17.93 and support at $16.56. The company's negative P/E ratio of -17.51, coupled with recent insider selling and a 'Strong Sell' overall rating from analysts, suggests a bearish short-to-medium term outlook. However, the breach of the long-term average could signal a potential buying opportunity for longer-term investors, provided further development supports a reversal. A stop-loss at $16.14 is recommended to mitigate risk given the stock's high volatility.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
StockInvest.us
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.